Design and baseline characteristics of the AMPLITUDE‐O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist-Reference-Cited by-同舟云学术

Design and baseline characteristics of the AMPLITUDE‐O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist

Published:2020-10-22 Issue:2 Volume:23 Page:318-323
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Gerstein Hertzel C.¹²^ORCID,Branch Kelley³,Heenan Laura¹,Del Prato Stefano⁴^ORCID,Khurmi Nardev S.⁵,Lam Carolyn S. P.⁶,Pratley Richard⁷,Rosenstock Julio⁸^ORCID,Sattar Naveed⁹^ORCID

Affiliation:

1. Population Health Research Institute Hamilton Health Sciences Hamilton Ontario Canada

2. McMaster University Hamilton Ontario Canada

3. Division of Cardiology University of Washington Seattle Washington USA

4. Department of Clinical & Experimental Medicine, Section of Metabolic Diseases and Diabetes University of Pisa Pisa Italy

5. Sanofi Bridgewater New Jersey USA

6. National Heart Centre Singapore and Duke‐National University of Singapore Singapore

7. AdventHealth Translational Research Institute Orlando Florida USA

8. Dallas Diabetes Research Center at Medical City Dallas Texas USA

9. Institute of Cardiovascular and Medical Sciences, University of Glasgow Glasgow UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14223

Reference16 articles.

1. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people

2. Resurgence in Diabetes-Related Complications

3. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials

4. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

5. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial;Diabetes, Obesity and Metabolism;2023-12-20

2. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD;American Journal of Kidney Diseases;2023-12

3. Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials;Diabetes, Obesity and Metabolism;2023-08-30

4. Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial;Circulation;2023-03-28

5. Series: Cardiovascular outcome trials for diabetes drugs.;British Journal of Diabetes;2022-12-21